Shopping Cart
Remove All
Your shopping cart is currently empty
Livmoniplimab (ABBV-151; ARGX-115) is a humanised monoclonal antibody targeting LRRC32 (GARP)/TGFβ1, which blocks TGFβ1 release mediated by LRRC32, for the treatment of locally advanced or metastatic solid tumours.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $257 | - | In Stock | |
| 5 mg | $668 | - | In Stock | |
| 10 mg | $1,070 | - | In Stock |
| Description | Livmoniplimab (ABBV-151; ARGX-115) is a humanised monoclonal antibody targeting LRRC32 (GARP)/TGFβ1, which blocks TGFβ1 release mediated by LRRC32, for the treatment of locally advanced or metastatic solid tumours. |
| In vivo | Method: Seven-week-old female B-hGARP mice were subcutaneously inoculated with MC38 mouse colon cancer cells to establish tumor models. Livmoniplimab was administered at a dose of 250 μg via intraperitoneal injection three times a week for 3 weeks to evaluate its antitumor efficacy. Result: Livmoniplimab treatment Resulted in a 34.3% inhibition of tumor growth. [2] |
| Synonyms | MHG-8, MHG8, ARGX-115, ARGX115, ABBV-151, ABBV151 |
| Cas No. | 2412004-88-5 |
| Color | Transparent |
| Appearance | Liquid |
| Storage | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.